| Title |
Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, June 2007
|
| DOI | 10.1007/s00280-007-0538-0 |
| Pubmed ID | |
| Authors |
Daniele Martarelli, Pierluigi Pompei, Caterina Baldi, Giovanni Mazzoni |
| Abstract |
Adrenocortical carcinoma is a rare tumor of the adrenal gland which requires new therapeutic approaches as its early diagnosis is difficult and prognosis poor despite therapies used. Recently, mebendazole has been proved to be effective against different cancers. The aim of our study was to evaluate whether mebendazole may result therapeutically useful in the treatment of human adrenocortical carcinoma. We analyzed the effect of mebendazole on human adrenocortical carcinoma cells in vitro and after implantation in nude mice. In order to clarify mechanisms of mebendazole action, metastases formation, apoptosis and angiogenesis were also investigated. Mebendazole significantly inhibited cancer cells growth, both in vitro and in vivo, the effects being due to the induction of apoptosis. Moreover, mebendazole inhibited invasion and migration of cancer cells in vitro, and metastases formation in vivo. Overall, these data suggest that treatment with mebendazole, also in combination with standard therapies, could provide a new protocol for the inhibition of adrenocortical carcinoma growth. |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 18% |
| Student > Master | 5 | 13% |
| Student > Ph. D. Student | 5 | 13% |
| Student > Bachelor | 4 | 11% |
| Student > Doctoral Student | 3 | 8% |
| Other | 5 | 13% |
| Unknown | 9 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 18% |
| Agricultural and Biological Sciences | 6 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 13% |
| Biochemistry, Genetics and Molecular Biology | 4 | 11% |
| Engineering | 2 | 5% |
| Other | 4 | 11% |
| Unknown | 10 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 August 2023.
All research outputs
#3,465,367
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#118
of 2,501 outputs
Outputs of similar age
#8,197
of 70,138 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#2
of 25 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 70,138 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.